Open-Label, Single Arm, Phase 3B, Multi-Center Study Evaluating the Efficacy of Venetoclax (ABT 199) in Relapsed/Refractory Subjects with Chronic Lymphocytic Leukemia (CLL) (VENICE I)
Phase of Trial: Phase III
Latest Information Update: 18 Aug 2017
At a glance
- Drugs Venetoclax (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Acronyms VENICE I
- Sponsors AbbVie
- 10 Jun 2017 Biomarkers information updated
- 19 Dec 2016 Planned End Date changed from 1 Mar 2021 to 1 Oct 2022.
- 06 Oct 2016 Planned primary completion date changed from 1 Aug 2020 to 1 Feb 2020.